| abstract |
The present invention relates to quinoline / quinoxaline compounds that inhibit platelet-derived growth factor or p56 Ick tyrosine kinase activity, pharmaceutical compositions comprising these compounds and methods of cell differentiation, proliferation, extracellular matrix production or mediator release and / or T cell activation And to the use of these compounds for treating patients susceptible to or susceptible to a disease / condition, including proliferation. |